0:00:01although i invariant ab and i'd like to give you a brief overview of my
0:00:05article new modalities the cancer treatment or non small cell lung cancer focus on the
0:00:11mean of their p
0:00:13in this article i review new immune based strategies that are being developed for the
0:00:17treatment of lung cancer which differ from conventional into cancer therapies
0:00:23chemotherapy and target agents at directly on the chamber
0:00:27most targeted agents in actively mutated proteins that give proved advantage to the tumour
0:00:33or a lot and that inhibit each you have receptor tire a stink i next
0:00:38and chris a native inhibit the l chi nice activity to prevent growth signalling
0:00:44that the system at points that jeff secreted by the tumour stopping blood vessel formation
0:00:49and starving the tumour
0:00:52tumours can dampen the body's natural immune response and i'm you know therapies are designed
0:00:56to increase the patient's own immune response to the chamber
0:01:00one approach is that use of tumour antigen vaccines
0:01:04many vaccines for lung cancer have reached the phase two or three trial stage of
0:01:08development
0:01:11another approach to counteract tumour really did you know suppression is we use of them
0:01:15you checkpoint inhibitors
0:01:18i mean chuck my pathways are used by the immune system to slow down or
0:01:22prepared t cell responses
0:01:25two of these pathways that have been the most heavily studied or the c t
0:01:29l a for and p d one have ways
0:01:33the immune checkpoint inhibitors under clinical study today are designed to prevent signaling through these
0:01:39pathways to restore anti tumour responses
0:01:43one c t l a for on the t cell lines it's like and on
0:01:48an antigen presenting sell the t cell becomes deactivated and does not mountain immune response
0:01:54to the tumour
0:01:55however in the presence of an anti c t l a for immune checkpoint inhibitor
0:02:01c t l a for is prevented from binding that's like in and the t
0:02:05cell becomes activated
0:02:07this t cell can now participate and then anti cancer immune response
0:02:13similarly when p d one and at some points it's like in on the tumour
0:02:17the t cell becomes deactivated
0:02:20however in the presence of an anti pt one immune checkpoint inhibitor p one is
0:02:26prevented from binding that's like in and the t cell becomes activated and can release
0:02:31side a lyric molecules to kill the tumour
0:02:35one t c t l a for me and checkpoint inhibitor if the luma map
0:02:39is approved for the treatment of advanced melanoma and has shown anti cancer activity and
0:02:45phase two trials of lung cancer
0:02:49there are several p d one halfway agents and development
0:02:52some targeting p d one and others targeting one of its like against p d
0:02:56l one
0:02:58no volume at a fully human and two p d one i mean checkpoint inhibitor
0:03:02has reported the most data to date and shows promising activity and lung cancer
0:03:09health care provider should be aware that in addition to traditional responses on conventional treatment
0:03:15responses have been observed with them you know therapies
0:03:18these are likely due to the immune mechanisms of action and include delayed responses or
0:03:24decrease tumour burden after an initial increase
0:03:28also side effects seen with the mean checkpoint inhibitors include adverse events that may be
0:03:33a be related in each are
0:03:35these select a ease may require more frequent monitoring and or unique intervention
0:03:41dermatological gastrointestinal and the crane eighties or among the most commonly reported
0:03:47although most are low grade select the ease can occur with rapid onset and prompt
0:03:53medical attention is critical to their management
0:03:57in the article i provide some key strategies that have been used for management of
0:04:01these eight using clinical studies
0:04:03to conclude my article provides an overview of the exciting them you know therapies that
0:04:08are in development for lung cancer